Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection

Jason Farley, David J. Dial, Marguerite Littleton-Kearney

Research output: Contribution to journalArticle

Abstract

An estimated 4 million persons are infected with hepatitis C, making it the most common chronic viral infection in the United States. Combination antiviral therapy with pegylated interferon alpha 2a (α-2a) or alpha 2b (α-2b) with ribavirin (RBV) (combination therapy) has become the mainstay of current hepatitis C virus (HCV) therapy. Control of treatment-related side effects is crucial to successful completion of combination therapy. This article outlines these therapies and reviews the literature detailing appropriate strategies for symptom management of the most common hematologic and neuropsychiatric side effects experienced with combination therapy for HCV.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalJournal for Nurse Practitioners
Volume2
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Therapeutics
Ribavirin
Hepatitis C
Antiviral Agents

Keywords

  • HCV treatment
  • Hepatitis C
  • Symptom management

ASJC Scopus subject areas

  • LPN and LVN
  • Fundamentals and skills

Cite this

Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection. / Farley, Jason; Dial, David J.; Littleton-Kearney, Marguerite.

In: Journal for Nurse Practitioners, Vol. 2, No. 1, 01.2006, p. 38-45.

Research output: Contribution to journalArticle

@article{6c69587d41654c5b95d98257aec7d990,
title = "Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection",
abstract = "An estimated 4 million persons are infected with hepatitis C, making it the most common chronic viral infection in the United States. Combination antiviral therapy with pegylated interferon alpha 2a (α-2a) or alpha 2b (α-2b) with ribavirin (RBV) (combination therapy) has become the mainstay of current hepatitis C virus (HCV) therapy. Control of treatment-related side effects is crucial to successful completion of combination therapy. This article outlines these therapies and reviews the literature detailing appropriate strategies for symptom management of the most common hematologic and neuropsychiatric side effects experienced with combination therapy for HCV.",
keywords = "HCV treatment, Hepatitis C, Symptom management",
author = "Jason Farley and Dial, {David J.} and Marguerite Littleton-Kearney",
year = "2006",
month = "1",
doi = "10.1016/j.nurpra.2005.11.012",
language = "English (US)",
volume = "2",
pages = "38--45",
journal = "Journal for Nurse Practitioners",
issn = "1555-4155",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Management of hematologic and neuropsychiatric side effects in treatment of chronic HCV infection

AU - Farley, Jason

AU - Dial, David J.

AU - Littleton-Kearney, Marguerite

PY - 2006/1

Y1 - 2006/1

N2 - An estimated 4 million persons are infected with hepatitis C, making it the most common chronic viral infection in the United States. Combination antiviral therapy with pegylated interferon alpha 2a (α-2a) or alpha 2b (α-2b) with ribavirin (RBV) (combination therapy) has become the mainstay of current hepatitis C virus (HCV) therapy. Control of treatment-related side effects is crucial to successful completion of combination therapy. This article outlines these therapies and reviews the literature detailing appropriate strategies for symptom management of the most common hematologic and neuropsychiatric side effects experienced with combination therapy for HCV.

AB - An estimated 4 million persons are infected with hepatitis C, making it the most common chronic viral infection in the United States. Combination antiviral therapy with pegylated interferon alpha 2a (α-2a) or alpha 2b (α-2b) with ribavirin (RBV) (combination therapy) has become the mainstay of current hepatitis C virus (HCV) therapy. Control of treatment-related side effects is crucial to successful completion of combination therapy. This article outlines these therapies and reviews the literature detailing appropriate strategies for symptom management of the most common hematologic and neuropsychiatric side effects experienced with combination therapy for HCV.

KW - HCV treatment

KW - Hepatitis C

KW - Symptom management

UR - http://www.scopus.com/inward/record.url?scp=33644842909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644842909&partnerID=8YFLogxK

U2 - 10.1016/j.nurpra.2005.11.012

DO - 10.1016/j.nurpra.2005.11.012

M3 - Article

AN - SCOPUS:33644842909

VL - 2

SP - 38

EP - 45

JO - Journal for Nurse Practitioners

JF - Journal for Nurse Practitioners

SN - 1555-4155

IS - 1

ER -